IMDX Stock Summary and Trading Ideas (Insight Molecular Diagnostics | NASDAQ:IMDX)

Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.

Insight Molecular Diagnostics trades on the NASDAQ stock market under the symbol IMDX.

As of October 9, 2026, IMDX stock price climbed to $3.37 with 150,697 million shares trading.

IMDX has a beta of 2.90, meaning it tends to be more sensitive to market movements. IMDX has a correlation of 0.15 to the broad based SPY ETF.

IMDX has a market cap of $110.28 million. This is considered a Micro Cap stock.

Last quarter Insight Molecular Diagnostics reported $239,000 in Revenue and -$.23 earnings per share. This fell short of revenue expectation by $-198,500 and met earnings estimates .

The top ETF exchange traded funds that IMDX belongs to (by Net Assets): VTI, VXF, IWC.

IMDX has underperformed the market in the last year with a price return of -8.4% while the SPY ETF gained +16.8%. IMDX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -29.6% and -14.7%, respectively, while the SPY returned +4.7% and +1.5%, respectively.

IMDX support price is $3.03 and resistance is $3.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMDX shares will trade within this expected range on the day.